Overview
Astellas Pharma of Tokyo researches, develops, manufactures, imports and exports pharmaceutical products; its products include Xtandi, Padcev, Xospata, Vyloy, Veozah, Izervay, Evrenzo, Betanis and Prograf.[2] Forbes records sales of US$14.2bn, up 13.2%, and profit of US$1.9bn.[2] It is the third Japanese company in the ranking. Forbes gives the company’s founding as April 1923, by Kenji Yamanouchi.[2] Its product list mixes established medicines such as Prograf with more recent launches such as Vyloy, Veozah and Izervay. Its market value is US$26.3bn.[2]
Astellas Pharma strengths and limitations
Strengths
- Sales growth of 13.2%
- Several newer launches
- Established in US and European markets
Limitations
- Smaller than Takeda and Otsuka
- Results translated from yen
- Smaller scale than Takeda
Appears in
Astellas Pharma peers and competitors
Companies ranked in the same lists as Astellas Pharma.
Johnson & Johnson- Amgen
Daiichi Sankyo
Viatris- Regeneron Pharmaceuticals
- CSL
Otsuka Holdings- Teva Pharmaceutical
Merck KGaA
Gilead Sciences
Takeda Pharmaceutical
GSK plc
Is this your company?
Update the description, logo, image and link through the submission form. Editors review every change.